Redmile Group
Latest statistics and disclosures from Redmile Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KRYS, FOLD, IMNM, SRRK, FATE, and represent 27.74% of Redmile Group's stock portfolio.
- Added to shares of these 10 stocks: SLN (+$44M), FDMT (+$40M), KROS (+$37M), STOK (+$33M), IMNM (+$25M), CI (+$24M), AKRO (+$19M), NRIX (+$18M), RGNX (+$17M), ARDX (+$16M).
- Started 16 new stock positions in CI, KROS, DGX, Boundless Bio, CYTK, ESTA, APLS, FDMT, ARDX, PGNY. BPMC, ICLR, MCK, LAB, ELAN, SLN.
- Reduced shares in these 10 stocks: , Rayzebio (-$116M), , KRYS (-$40M), CTLT (-$26M), CRL (-$21M), FOLD (-$19M), CABA (-$16M), BHVN (-$15M), PEN (-$11M).
- Sold out of its positions in BCEL, CRL, ImmunoGen, NVTAQ, MDVLQ, Rayzebio, SPY, Science 37 Holdings, Somalogic.
- Redmile Group was a net seller of stock by $-414M.
- Redmile Group has $2.7B in assets under management (AUM), dropping by -2.55%.
- Central Index Key (CIK): 0001425738
Tip: Access up to 7 years of quarterly data
Positions held by Redmile Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Redmile Group
Redmile Group holds 77 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Krystal Biotech (KRYS) | 9.8 | $268M | -12% | 1.5M | 177.93 |
|
| Amicus Therapeutics (FOLD) | 5.7 | $156M | -10% | 13M | 11.78 |
|
| Immunome (IMNM) | 4.4 | $121M | +26% | 4.9M | 24.68 |
|
| Scholar Rock Hldg Corp (SRRK) | 4.2 | $114M | 6.4M | 17.76 |
|
|
| Fate Therapeutics (FATE) | 3.5 | $97M | 13M | 7.34 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 3.5 | $96M | +21% | 4.6M | 21.07 |
|
| Deciphera Pharmaceuticals (DCPH) | 3.1 | $83M | +10% | 5.3M | 15.73 |
|
| Kymera Therapeutics (KYMR) | 2.6 | $70M | -4% | 1.7M | 40.20 |
|
| Adc Therapeutics Sa SHS (ADCT) | 2.5 | $69M | 15M | 4.49 |
|
|
| Stoke Therapeutics (STOK) | 2.5 | $69M | +93% | 5.1M | 13.50 |
|
| Augmedix (AUGX) | 2.5 | $67M | 16M | 4.09 |
|
|
| Nurix Therapeutics (NRIX) | 2.4 | $66M | +37% | 4.5M | 14.70 |
|
| Biohaven (BHVN) | 2.3 | $64M | -19% | 1.2M | 54.69 |
|
| Beam Therapeutics (BEAM) | 2.3 | $62M | +31% | 1.9M | 33.04 |
|
| Zymeworks Del (ZYME) | 2.1 | $59M | -3% | 5.6M | 10.52 |
|
| Livanova SHS (LIVN) | 2.1 | $58M | -8% | 1.0M | 55.94 |
|
| Shattuck Labs (STTK) | 1.8 | $50M | 5.6M | 8.94 |
|
|
| Alx Oncology Hldgs (ALXO) | 1.8 | $48M | +18% | 4.3M | 11.15 |
|
| Neurogene (NGNE) | 1.7 | $48M | 935k | 50.90 |
|
|
| Akero Therapeutics (AKRO) | 1.7 | $47M | +67% | 1.9M | 25.26 |
|
| Absci Corp (ABSI) | 1.7 | $47M | +2% | 8.3M | 5.68 |
|
| Pliant Therapeutics (PLRX) | 1.7 | $46M | +14% | 3.1M | 14.90 |
|
| Silence Therapeutics Ads (SLN) | 1.6 | $44M | NEW | 2.0M | 21.60 |
|
| Ideaya Biosciences (IDYA) | 1.5 | $41M | 923k | 43.88 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 1.5 | $40M | NEW | 1.3M | 31.86 |
|
| Annexon (ANNX) | 1.4 | $40M | 5.5M | 7.17 |
|
|
| Boston Scientific Corporation (BSX) | 1.4 | $38M | -19% | 561k | 68.49 |
|
| Celldex Therapeutics Com New (CLDX) | 1.4 | $38M | -9% | 897k | 41.97 |
|
| Keros Therapeutics (KROS) | 1.3 | $37M | NEW | 553k | 66.20 |
|
| Catalent (CTLT) | 1.3 | $36M | -42% | 633k | 56.45 |
|
| Immunovant (IMVT) | 1.1 | $31M | 970k | 32.31 |
|
|
| Replimune Group (REPL) | 1.1 | $31M | -3% | 3.7M | 8.17 |
|
| Abbott Laboratories (ABT) | 1.1 | $30M | 262k | 113.66 |
|
|
| Igm Biosciences (IGMS) | 1.1 | $30M | +3% | 3.1M | 9.65 |
|
| Align Technology (ALGN) | 1.1 | $29M | +74% | 87k | 327.92 |
|
| Cogent Biosciences (COGT) | 1.0 | $27M | +35% | 4.0M | 6.72 |
|
| 89bio (ETNB) | 1.0 | $26M | +14% | 2.3M | 11.64 |
|
| Cigna Corp (CI) | 0.9 | $24M | NEW | 65k | 363.19 |
|
| Evolent Health Cl A (EVH) | 0.8 | $22M | -18% | 679k | 32.79 |
|
| Verve Therapeutics (VERV) | 0.8 | $21M | -6% | 1.6M | 13.28 |
|
| Entrada Therapeutics (TRDA) | 0.7 | $18M | 1.3M | 14.17 |
|
|
| Hca Holdings (HCA) | 0.6 | $18M | -20% | 53k | 333.53 |
|
| Anthem (ELV) | 0.6 | $16M | +35% | 31k | 518.54 |
|
| Ardelyx (ARDX) | 0.6 | $16M | NEW | 2.2M | 7.30 |
|
| Boundless Bio | 0.6 | $16M | NEW | 1.1M | 14.25 |
|
| Stryker Corporation (SYK) | 0.6 | $16M | -18% | 43k | 357.87 |
|
| Gritstone Oncology Ord (GRTS) | 0.5 | $15M | -2% | 5.8M | 2.57 |
|
| Prime Medicine (PRME) | 0.5 | $15M | +56% | 2.1M | 7.00 |
|
| Icon SHS (ICLR) | 0.5 | $12M | NEW | 37k | 335.95 |
|
| Progyny (PGNY) | 0.4 | $12M | NEW | 321k | 38.15 |
|
| Ventyx Biosciences (VTYX) | 0.4 | $12M | +944% | 2.2M | 5.50 |
|
| Intuitive Surgical Com New (ISRG) | 0.4 | $12M | -45% | 30k | 399.09 |
|
| Cytokinetics Com New (CYTK) | 0.4 | $11M | NEW | 162k | 70.11 |
|
| Quest Diagnostics Incorporated (DGX) | 0.4 | $11M | NEW | 84k | 133.11 |
|
| McKesson Corporation (MCK) | 0.4 | $11M | NEW | 21k | 536.85 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.4 | $11M | 3.0M | 3.64 |
|
|
| Elanco Animal Health (ELAN) | 0.4 | $11M | NEW | 676k | 16.28 |
|
| Blueprint Medicines (BPMC) | 0.4 | $11M | NEW | 113k | 94.86 |
|
| Penumbra (PEN) | 0.4 | $10M | -53% | 45k | 223.18 |
|
| Repare Therapeutics Ord (RPTX) | 0.3 | $9.5M | -6% | 2.0M | 4.71 |
|
| Apellis Pharmaceuticals (APLS) | 0.3 | $9.1M | NEW | 155k | 58.78 |
|
| Stereotaxis Com New (STXS) | 0.3 | $8.6M | -2% | 3.3M | 2.61 |
|
| Cabaletta Bio (CABA) | 0.3 | $7.6M | -67% | 443k | 17.06 |
|
| Lava Therapeutics Nv SHS (LVTX) | 0.3 | $6.9M | 2.1M | 3.33 |
|
|
| Atara Biotherapeutics (ATRA) | 0.2 | $6.4M | 9.3M | 0.69 |
|
|
| Adagio Therapeutics (IVVD) | 0.2 | $6.4M | 1.4M | 4.44 |
|
|
| Rapt Therapeutics (RAPT) | 0.2 | $5.9M | +80% | 662k | 8.98 |
|
| Ac Immune Sa SHS (ACIU) | 0.2 | $5.9M | 2.0M | 2.96 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 0.2 | $5.8M | NEW | 114k | 50.90 |
|
| Allakos (ALLK) | 0.2 | $4.3M | -5% | 3.5M | 1.26 |
|
| Xeris Pharmaceuticals (XERS) | 0.1 | $2.3M | 1.0M | 2.21 |
|
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $2.0M | 1.6M | 1.25 |
|
|
| Allovir (ALVR) | 0.1 | $1.4M | 1.9M | 0.75 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.0 | $1.1M | 716k | 1.58 |
|
|
| D Fluidigm Corp Del (LAB) | 0.0 | $1.1M | NEW | 412k | 2.71 |
|
| Hookipa Pharma Inc equity (HOOK) | 0.0 | $757k | 1.1M | 0.71 |
|
|
| Alpha Teknova (TKNO) | 0.0 | $434k | +6% | 172k | 2.53 |
|
Past Filings by Redmile Group
SEC 13F filings are viewable for Redmile Group going back to 2010
- Redmile Group 2024 Q1 filed May 15, 2024
- Redmile Group 2023 Q4 filed Feb. 14, 2024
- Redmile Group 2023 Q3 filed Nov. 14, 2023
- Redmile Group 2023 Q2 filed Aug. 14, 2023
- Redmile Group 2023 Q1 filed May 15, 2023
- Redmile Group 2022 Q4 filed Feb. 14, 2023
- Redmile Group 2022 Q3 filed Nov. 14, 2022
- Redmile Group 2022 Q2 filed Aug. 15, 2022
- Redmile Group 2022 Q1 filed May 16, 2022
- Redmile Group 2021 Q4 filed Feb. 14, 2022
- Redmile Group 2021 Q3 filed Nov. 15, 2021
- Redmile Group 2021 Q2 filed Aug. 16, 2021
- Redmile Group 2021 Q1 filed May 17, 2021
- Redmile Group 2020 Q4 filed Feb. 16, 2021
- Redmile Group 2020 Q3 filed Nov. 16, 2020
- Redmile Group 2020 Q2 filed Aug. 14, 2020